Dergiler / Marmara Pharmaceutical Journal / 2017 / Cilt: 21 - Sayı: 2

RP-HPLC Estimation of Alogliptin and Pioglitazone Simultaneously in Combined Tablet Dosage Forms

Sayfa
345–354
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The developed and validated method was successfully applied for the simultaneous determination of alogliptin and pioglitazone in tablet formulation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:A high performance liquid chromatographic method was developed to quantify alogliptin and pioglitazone simultaneously in bulk and combined tablet dosage form.
📊
Temel Bulgular & Veri:The chromatographic analysis was done on a Zorbax C8 column (150 mm x 4.6 mm internal diameter, 5 μm particle size) with a mobile phase of 0.1 M ammonium acetate and methanol (50:50, v/v) at 1.0 mL/min.
💡
Sonuç & Katkı:The developed and validated method was successfully applied for the simultaneous determination of alogliptin and pioglitazone in tablet formulation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

A high performance liquid chromatographic method was developed to quantify alogliptin and pioglitazone simultaneously in bulk and combined tablet dosage form. The chromatographic analysis was done on a Zorbax C8 column (150 mm x 4.6 mm internal diameter, 5 μm particle size) with a mobile phase of 0.1 M ammonium acetate and methanol (50:50, v/v) at 1.0 mL/min. The effluents were monitored at 248 nm and the retention time of alogliptin and pioglitazone were 2.883 min and 4.329 min, respectively. Calibration curves were linear from 6.25-18.75 μg/mL for alogliptin and 11.25-33.75 μg/mL for pioglitazone. The LOD and LOQ values for alogliptin were 0.047 and 0.157 μg/mL, respectively; corresponding values for pioglitazone were 0.085 and 0.284 μg/ mL, respectively. The precision for alogliptin and pioglitazone was in the range of 0.094-0.303% and 0.072-0.239%, respectively, with corresponding accuracy of 99.450-99.692% and 100.184-100.422%. The developed and validated method was successfully applied for the simultaneous determination of alogliptin and pioglitazone in tablet formulation.

🔖

Bu Makaleye Atıf Yap

HARİBABU, B., VENİ, P. R. K., KRİSHNA, K. B. M., PRAMEELA, K. L. (2017). RP-HPLC Estimation of Alogliptin and Pioglitazone Simultaneously in Combined Tablet Dosage Forms. Marmara Pharmaceutical Journal, Cilt: 21 - Sayı: 2, 345–354. https://ajindex.com/articles/283748

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidylpeptidase-4 inhibitor for type 2 diabetes mellitus. AnnPharmacother 2013; 47: 1532-9.
  2. Marino AB, Cole SW. Alogliptin: safety, efficacy and clinicalimplications. J Pharm Pract 2015; 28: 99-106.
  3. Golightly LK, Drayna CC, McDermott MT. Comparativeclinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Clin Pharmacokinet 2012; 51: 501-14.
  4. Cyrus VD, Vijay S. Pioglitazone in the Treatment of Type2 Diabetes: Safety and Efficacy Review. Clin Med InsightsEndocrinol Diabetes 2010; 3: 43-51.
  5. Brunetti L, Kalabalık J. Management of Type-2 diabetesmellitus in adults. Focus on individualizing non-insulintherapies. P & T 2012; 37: 687-96. van Raalte DH, van Genugten RE, Eliasson B, Moller-GoedeDL, Mari A, Tura A, Wilson C, Fleck P, Taskinen MR, SmithU, Diamant M. The effect of alogliptin and pioglitazonecombination therapy on various aspects of β-cell function inpatients with recent-onset type 2 diabetes. Eur J Endocrinol2014; 170: 565-74.
  6. Julio R, Silvio EI, Jochen S, Penny RF, Craig AW, Qais M.Initial combination therapy with alogliptin and pioglitazonein drug-naive patients with type 2 diabetes. Diabetes Care2010; 33: 2406-8. ht t p: / / www. fd a. gov / Ne wsEv e nt s / Ne w s ro om/PressAnnouncements/ucm336942.htm Raval K, Srinivasa U. First order derivative and dualwavelength spectrophotometry methods development andvalidation for simultaneous estimation. Int J Pharm PharmaSci 2014; 6: 730-8.
  7. Anusha M, Manzoor A, Satishkumar SA, Vijaya KCA.Simultaneous estimation of alogliptin and piogliazone in bulkand combined tablet dosage form by UV-spectrophotometricmethods. Int J Uni Pharma Bio Sci 2014; 3: 363-76.
  8. Komal S, Amrita P. Development and validation of HPTLCmethod for simultaneous estimation of alogliptin benzoateand pioglitazone hydrochloride in bulk drugs and combineddosage forms. Int J Pharma Res Rev 2015; 4: 35-42.
  9. Raval K, Srinivasa U. Development and validation of HPLCmethod for the simultaneous estimation of pioglitazone andalogliptin in bulk and dosage form. Int J Cur Res 2014; 6:10201-7.
  10. Neelima B, Kumar PR, Bindu VH, Prasad YR. A validatedstability indicating RP-HPLC method for simultaneousdetermination of alogliptine and pioglitazone in bulk andpharmaceutical formulations. Int J Pharm 2014; 4: 458-64.
  11. Manzoor A, Anusha M, Satishkumar SA, Kuppast IJ,Siddalingaswamy MS, Ravi MC. RP-HPLC methoddevelopment and validation for simultaneous estimation ofalogliptin and pioglitazone in combined t